---
type: "Nootropic"
title: "vinpocetine"
description: "Vinpocetine is a vasoactive synthetic compound studied in older patient trials. Rapid focus or memory enhancement in healthy people is not established; a blood-flow mechanism alone does not establish cognitive benefit."
resource: "https://nootropikler.com/nootropics/vinpocetine"
tags: ["Blood Flow", "Focus", "memory"]
timestamp: 2026-11-11T00:00:00Z
category: "cognitive"
source: "semi-synthetic"
latin: "Vinpocetine - Ethyl apovincaminate"
language: "en"
---

# vinpocetine

*Vinpocetine - Ethyl apovincaminate*

Vinpocetine is a vasoactive synthetic compound studied in older patient trials. Rapid focus or memory enhancement in healthy people is not established; a blood-flow mechanism alone does not establish cognitive benefit.

## Quick profile

| Property | Value |
| --- | --- |
| Onset of Effect | No established timeframe |
| Half life | No established timeframe |
| Dose used in research | Depends on the studied product and protocol |
| Safety | See detailed safety warnings |
| Level of Evidence | Limited human data; cognitive benefit uncertain |

> Correction · 2026-11-11: Removed generalized dose, half-life and mechanism claims. Linked the dementia review and pregnancy warning to their sources.

> **Important Note:** FDA’s 2019 warning advises pregnant women and women who could become pregnant not to take vinpocetine because of miscarriage or fetal-development risks. Its 2016 dietary-supplement definition position is a separate issue. Anticoagulants, blood-pressure medicines and bleeding risk need medical review.

## What is Vinpocetine?

Vinpocetine is a synthetic ethyl ester of apovincamine.

## Mechanism of Effect

## Clinical Evidence

Hindmarch et al. (1991) studied 203 patients with organic psychosyndromes, not healthy older adults, for 16 weeks with placebo or vinpocetine 3×10/3×20 mg daily. Subhan and Hindmarch (1985) yielded short-term, limited test findings in 12 healthy women, not evidence of general cognitive enhancement.

## Dose information and research limits

> **Dose information and research limits:** This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.


## Frequently Asked Questions

### What does vinpocetine do?

Vinpocetine is a vasoactive synthetic compound studied in older patient trials. Rapid focus or memory enhancement in healthy people is not established; a blood-flow mechanism alone does not establish cognitive benefit.

### What should be the dose of vinpocetine?

Hindmarch et al. (1991) studied 203 patients with organic psychosyndromes, not healthy older adults, for 16 weeks with placebo or vinpocetine 3×10/3×20 mg daily. Subhan and Hindmarch (1985) yielded short-term, limited test findings in 12 healthy women, not evidence of general cognitive enhancement.

### What are the side effects of vinpocetine?

FDA’s 2019 warning advises pregnant women and women who could become pregnant not to take vinpocetine because of miscarriage or fetal-development risks. Its 2016 dietary-supplement definition position is a separate issue. Anticoagulants, blood-pressure medicines and bleeding risk need medical review.

### Is vinpocetine legal in Türkiye and where can it be obtained?

Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.

### When does the effect of vinpocetine begin and how long does it last?

No established timeframe

## Sources

- Hindmarch I, et al. (1991). Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. *International Clinical Psychopharmacology*, 6(1), 31–43. [PubMed · PMID 2071888](https://pubmed.ncbi.nlm.nih.gov/2071888/)
- Subhan Z & Hindmarch I (1985). Psychopharmacological effects of vinpocetine in normal healthy volunteers. *European Journal of Clinical Pharmacology*, 28(5), 567–571. [PubMed · PMID 3899677](https://pubmed.ncbi.nlm.nih.gov/3899677/)
- Bereczki D & Fekete I (2008). Vinpocetine for acute ischaemic stroke. *Cochrane Database of Systematic Reviews*, (1), CD000480. [PubMed · PMID 18253980](https://pubmed.ncbi.nlm.nih.gov/18253980/)
- Valikovics A (2007). Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. *Ideggyogy Sz*, 60(7–8), 301–310. [PubMed · PMID 17713111](https://pubmed.ncbi.nlm.nih.gov/17713111/)
- Kemény V, et al. (2005). Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients. *Journal of Clinical Pharmacology*, 45(9), 1048–54. https://doi.org/10.1177/0091270005279363 [PubMed · PMID 16100299](https://pubmed.ncbi.nlm.nih.gov/16100299/)
- US Food and Drug Administration. Vinpocetine in Dietary Supplements. https://www.fda.gov/food/information-select-dietary-supplement-ingredients-and-other-substances/vinpocetine-dietary-supplements [US Food and Drug Administration](https://www.fda.gov/food/information-select-dietary-supplement-ingredients-and-other-substances/vinpocetine-dietary-supplements)
- Szatmari SZ, Whitehouse PJ. (2003). Vinpocetine for cognitive impairment and dementia. *Cochrane Database of Systematic Reviews*, (1), CD003119. [PubMed · PMID 12535455](https://pubmed.ncbi.nlm.nih.gov/12535455/)

## Related nootropics

- [Ginkgo Biloba](/okf/nootropics/ginkgo-biloba.md)
- [CDP-Choline](/okf/nootropics/cdp-choline.md)
- [Omega-3 DHA/EPA](/okf/nootropics/omega-3.md)
